Gilles Huberfeld – MD, PhD

Maitre de Conférence des Universités et Praticien Hospitalier (Associate Professor) – Sorbonne Université, Paris, France.

Neurologist, Neurophysiologist, Researcher

Clinical position: Clinical Neurophysiology department – Pitié-Salpêtrière University Hospital, Assistance Publique – Hôpitaux de Paris (since 2010)

Science position:   Researcher at the “Neuroglial Interactions in Cerebral Physiopathology” team, Center for Interdisciplinary Research in Biology, College de France, CNRS UMR 7241 INSERM U1050, Paris (since 2019)

Researcher unique identifiers: ORCID: 0000-0001-8120-0300 – Research ID B-1450-2019

Research activity

My research focuses on: 1) the emergence and dynamics of synchronous (epileptic) neuronal and glial activities in vitro, both at the cellular and network level, 2) the dynamics of GABAergic signaling and ions affecting excitability (chloride and potassium), 3) the interactions between epileptogenesis processes and brain injuries with a special focus on gliomas, 4) eHealth dedicated to epileptology.

As a physiologist, I use electrophysiological approaches in vivo (ECoG) and in vitro (extracellular recordings, tetrodes, Multi Electrode Arrays – patch-clamp and sharp electrode cell recordings), and favor the study of post-operative human tissues, cortical and hippocampal. The goal of my research is to characterize cellular defects and the dynamics of the emergence of epileptic activity in human tissues in order to design innovative anti-epileptic strategies.

During my thesis, I studied the genesis of epileptic activities in rodents and humans (post-operative tissues) in hippocampal structures, in vitro. The subiculum, the output area of the hippocampus, generates spontaneous interictal epileptic discharges similar to those recorded in vivo. These epileptic activities are initiated by interneurons paradoxically depolarizing, and even exciting, 1/5 pyramidal cells, instead of controlling their activity by hyperpolarizing. These depolarizing effects of GABA are related to disturbances of chloride homeostasis that underlie GABAergic currents. Rebalancing neuronal chloride by the diuretic bumetanide blocks the epileptic activities, constituting a new potential anti-epileptic strategy.

During my post-doctoral fellowship, I studied the ictogenesis processes in human tissues by exploring the transition between the interictal state and the crisis, induced pharmacologically by increased excitability. This period is characterized by the emergence of specific synchronous population activities: pre-ictal discharges. Preictal discharges cluster to initiate seizures but they emerge gradually during the transition period lasting several tens of minutes. They differ from interictal events in their signature, cellular base and pharmacology. They are initiated by a subpopulation of pyramidal cells that synchronize most local cells via AMPA glutamatergic signaling (whereas inter-critical events are triggered by interneurons that depolarize 1/5 of the pyramidal cells that present an increased chloride concentration). Pre-ictal discharges emerge in cases of hyperexcitability, whereas interictal events depend on epileptogenic remodeling in the tissue. Once mature, recurrent pre-ictal discharges trigger seizures, locally recruiting and synchronizing various cell populations.

Since 2010 (Associate Professor in Physiology), I continue my research on human epileptic tissues, expanding investigations to other lesion types. The neocortex surrounding infiltrating gliomas is removed with the tumor for oncological reasons, but many patients have epileptic seizures. In vitro, these tissues produce spontaneous epileptic discharges, allowing studies on tissue remodeling and the local circuits producing epileptic events. These activities are very focal and are sustained by GABAergic depolarizing inputs driven by interneurons. In vitro studies have suggested a link between epileptic activities and cortical infiltration by tumor cells spreading around the glioma. Chloride regulation, altered both within neurons and in migrating tumor cells, accounts for epileptic discharges and tumor invasion, respectively. Such common pathways suggest that therapies may target both epilepsy and oncological processes. More recently, we have shown that in focal cortical dysplasias, similar depolarizing GABAergic effects were involved in the genesis of epileptic activities.

My current projects aim at studying the characteristics of other types of epileptogenic tissues and the mechanisms of seizure generation. I wish to identify the cellular interactions (pyramidal cells vs. interneurons, influenced by astrocytes) leading to the appearance of an ictal event. The working hypothesis and preliminary data indicate that recurrence of pre-ictal discharges may increase the amount of GABA-excited neurons in a specific time window during which intracellular chloride concentration (driving GABAergic currents) in balance with external potassium (affecting local excitability) would overcome regulation processes to trigger the seizure. 

Our team has also recently identified one of the first specific ictogenesis target. Membrane channels pannexins 1 are expressed by epileptic tissues and open during the transition to seizure process allowing blockers to prevent seizure generation during this specific period. Moreover, such blockers were shown to be efficient in various epileptic conditions and to have safe profiles with no clear effect on basal / physiological neuronal activities. 

As a neurophysiology clinician I am also involved in the development of in vivo programs. We are currently recording the cortex of patients harboring gliomas and undergoing surgery in awake conditions. These recordings will be soon performed with innovative microelectrodes characterized by optimal spatio-temporal sampling. From these recordings real-time mapping of epileptic biomarkers such as high frequency oscillations, will be extracted and displayed directly on the cortex to assist the neurosurgeon. I have finally developed an application for patients with epilepsy that will be associated with EEG recordings from earplugs and big data analysis.

My main collaborators are:

Michel Le Van Quyen, Laboratory of Biomedical Imaging, Sorbonne University, Paris: signal analysis and high frequency oscillations.

Marc Sanson, Experimental Neuro-oncology group, ICM, Paris: oncological effects of IDH mutations

Laurent Capelle, Neurosurgery, Pitié-Salpêtrière hospital, Sorbonne University, Paris & Johan Pallud, Neurosurgery, Hôpital Ste-Anne, Université ParisDescartes, Paris: gliomas and epileptogenicity, cortical peroperative recordings, postoperative tissues analysis

Liset Menendez de la Prida, Instituto Cajal – CSIC, Madrid, Spain. Rhythms and epilepsy in human tissues.

Clinical activity

Neurophysiology: EEG, intraoperative ElectroCorticOGraphy
Epileptology with a special interest for tumor related epilepsy

Teaching activity

Sorbonne University (Medicine students, Neuroscience master student, Psychomotricity and speech therapist school, University diploma to graduated neurologists): basic neuroscience, synaptic plasticity, epilepsies (basic phenomenon, clinics, neurophysiology), Neurophysiology (EEG, basis, analysis and applications), Comas, eHealth.

Clinical teaching at hospital to students and residents: EEG and epilepsy.



2013             HDR (Habilitation thesis) « Genesis of epileptic activities by human tissue in vitro »

2001-2007        PhD in Neurosciences (UPMC University – Paris). Genesis of epileptic activities by   hippocampal structures (supervisor Dr R Miles).

1999-2000        Master in Neurosciences (UPMC University – Paris, Rank: 1st)


2003                  University certifications in Epileptology 

2001                  Habilitation in Neurology (UPMC University – Paris)

2002                  Doctor of Medicine (UPMC University – Paris)

1999                  University certificate in Clinical Neurophysiology

1995-2001          Neurology Fellowship (Paris)

1995                  “Internat” concours (Medicine, Paris – Ile de France, Rank: 6th / > 6000 candidates).

1989-1995          Medical school: Université de Bourgogne (Dijon, France)

Previous Positions

Principal Investigator

2014-2018        PI: INSERM U1129 – Infantile Epilepsies and Brain Plasticity – Hôpital Necker – Paris, France

2010-2013        PI: Institut du Cerveau et de la Moelle épinière – Cortex & Epilepsy team – INSERM UMRS 975 – CNRS UMR 7225 – UPMC University – Paris, France)


2007-2010        Postdoc: INSERM junior position, Institut du Cerveau et de la Moelle épinière – Cortex & Epilepsy team – INSERM UMRS 975 – CNRS UMR 7225 – UPMC University, Paris

2008                Contrat Junior INSERM (Postdoc salary for 5 years)

2008                Inter University prize Prix « Chancellerie des Universités », Paris (10 000€).

2005-2007        Assistant Hospitalo-Universitaire (Assistant Professor). Clinic: Epilepsy Unit (Pitié-Salpêtrière hospital)

2003-2005        Chef de Clinique – Assistant (Assistant Professor) UPMC University – Paris. Clinic: Rehabilitation Unit (Pitié-Salpêtrière hospital) 

2001-2007        PhD: INSERM U 739 “Cortex & Epilepsy” laboratory – UPMC University – Paris

2001                 Assistant Hopitalier de Recherche CNRS contract (PhD Salary for 2 years)        

1999-2000        Neuroscience Master: Laboratory INSERM U 789 ‘Mechanism and consequences of neuronal death’, Hôpital Pitié-Salpêtrière, UPMC University – Paris

Institutional responsibilities

2010-               Member of the Scientific committee of the Ligue Française Contre l’Epilepsie

2010-               Member of the Comité de Protection des Personnes (CPP) Ile de France VI (local french ethical comity)

2012-               Member of the Scientific committee of the Fédération Française pour la Recherche en Epileptologie (FFRE French Federation or Research in Epilepsy)

2014-               Member of the Scientific committee of the start-up AdPueriVitam (APV) developing drugs for pediatric epilepsies

2018-               Member of the RENOCLIP group on Neuroglial Tumors (ANOCEF)

2019-               Member of the Collégiale de Physiologie hôpitaux universitaires de Paris


Huberfeld G, Kubis N, Lot G, Ripoll L, Chaine P, Drouet L & Woimant F. G20210a prothrombin gene mutation in two siblings with cerebral venous thrombosis. Neurology1998; 51(1): 316-7.

 Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, Escayg A, MacDonald BT, Meisler MH, Moulard B, Chaigne D, Buresi C & Malafosse A. Mutations of scn1a, encoding a neuronal sodium channel, in two families with GEFS+. Nat Genet2000; 24(4): 343-5.

Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M & Gajdos P. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol2000; 247(4): 286-90.

Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud’homme JF, Baulac M, Brice A, Bruzzone R & LeGuern E. First genetic evidence of gaba(a) receptor dysfunction in epilepsy: A mutation in the gamma2-subunit gene. Nat Genet2001; 28(1): 46-8.

Huberfeld G, Dupont S, Hazemann P, Adam C, Baulac M & Pierrot-Deseilligny C. Recurrent idiopathic stupor in a patient: Responsability of exogenous or endogenous benzodiazepines?. Rev Neurol (Paris)2002; 158(8-9): 824-6.

Cohen I, Navarro V, Huberfeld G, Clemenceau S, Baulac M & Miles R. Response to comment on « on the origin of interictal activity in human temporal lobe epilepsy in vitro ». Science2003; 301(5632): 463.

Baulac S, Gourfinkel-An I, Nabbout R, Huberfeld G, Serratosa J, Leguern E & Baulac M. Fever, genes, and epilepsy. Lancet Neurology2004; 3(7):421-30.

Huberfeld G, Habert MO, Clemenceau S, Maksud P, Baulac M & Adam C. Contralateral propagation of epileptic seizures studied with SPECT: the Mirror Image. Epilepsia 2006; 47(1):123-133.

Menendez de la Prida L, Huberfeld G, Cohen I & Miles R. Threshold Behavior in the Initiation of Hippocampal Population Bursts. Neuron2006; 49(1):131–42.

CohenI, Huberfeld G& Miles R. Emergence of disinhibition induced synchrony in the CA3 region of the hippocampus in vitro. J Physiol 2006;570(Pt 3):583-94.

Huberfeld G, Wittner L, Kaila K, Clemenceau S, Miles R & Rivera C. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 2007;27(37):9866–9873.

Pallud J, Devaux B, Miles R, Huberfeld G.Hippocampal Seizures. J Neurosurg2009;110:399.

Wittner L, Huberfeld G, Clemenceau S, Erőss L, Dezamis E, Entz L, Ulbert I, Baulac M & Miles R. The epileptic human hippocampal CA2 region generates spontaneous interictal like activity in vitro. Brain 2009;132(11):3022-46.

Huberfeld G, Menendez de la Prida L, Pallud J, Cohen I, LevanQuyen M, Clemenceau S, Baulac M & Miles R. Glutamatergic pre-ictal discharges emerge at the transition to seizure in the human epilepsy. Nature Neurosciences 2011;14(5):627-34.

Sabolek H, Swiercz W, Lillis K, Cash S, Huberfeld G, Zhao G, Ste-Marie L, Clemenceau S, Barsh G, Miles R, Staley K. A candidate mechanism underlying the variance of interictal spike propagation. J Neurosci 2012; 32(9):3009-21

Degos B, Daelman L, Huberfeld G, Meppiel E, Rabier D, Galanaud D, Magis G, Lyon-Caen O, Samuel D, Sedel F. Portosystemic shunts: An underdiagnosed but treatable cause of neurological and psychiatric disorders. Journal of the Neurological Sciences2012 ;321(1-2):58-64.

Huberfeld G, Le Duigou C, Le Van Quyen M, Navarro V, Baulac M & Miles R. The paradox of the paroxysm: can human seizure precipitants help understand ictogenesis? The Neuroscientist 2013;19(5):523-40

Pallud J, Capelle L,Huberfeld G. Tumoral epileptogenicity: How does it happen? Epilepsia2013 ;54(Suppl 9):30-4

Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G. Epileptic seizures in diffuse low-grade gliomas in adults. Brain2014;137(Pt 2):449-62

Pallud J, Le Van Quyen M, Bielle F, Pellegrino Ch, Varlet P, Labussiere M, Cresto N, Dieme MJ, Baulac M, Duyckaerts C, Kourdougli N, Chazal G, Deveaux B, Rivera C, Miles R, Capelle L, Huberfeld G. Cortical GABAergic excitation contributes to epileptic activities around human glioma. Science Translational Medicine 2014; 6(244): 244ra89.

Blauwblomme T, Jiruska P, Huberfeld G. Mechanisms of ictogenesis.International Review of Neurobiology2014 ; 114: 155-85.

Huberfeld G, Becker AJ. Commentary: Morris-Coole/Epilepsia prize. Epilepsia2014 ; 55(5): 640-1.

Dossi E, Blauwblomme T, Nabbout R, Huberfeld G, Rouach N. Multi-electrode array recordings of human epileptic postoperative cortical tissue. J Vis Exp. 2014 26;(92).

Alvarado-Rojas C, Huberfeld G, Baulac M, Clemenceau S, Charpier S, Miles R, Menendez de la Prida L, Le Van Quyen M. Different mechanismscontribute to ripple-like oscillations (100-250 Hz) in the human epileptic subiculum in vitro. Ann Neurol2015;77(2):281-90

Huberfeld G, Blauwblomme T, Miles R. Hippocampus and epilepsy: findings from human tissues. Rev Neurol (Paris)2015 ; S0035-3787(15)00589-5        

Huberfeld G, Pallud J. Brain tumors-related epilepsy. Pratique Neurologique – FMC 2015;6:19–33.

Huberfeld G, Kubis N. Electroencephalography in Intensive Care Unit. Réanimation 2015. DOI 10.1007/s13546-015-1098-7

Huberfeld G, Vecht Ch. Seizures and gliomas – towards a single therapeutic approach. Nature Review Neurology2016;12(4): 204-16.

Gataullina S, Lemaire E, Wendling F, Kaminska A, Watrin F, Riquet A, Ville D, Moutard ML, de Saint Martin A, Napuri S, Pedespan JM, Eisermann M, Bahi-Buisson N, Nabbout R, Chiron C, Dulac O, Huberfeld G. Epilepsy in young Tsc1(+/-) mice exhibits age-dependent expression that mimics that of human tuberous sclerosis complex.  Epilepsia. 2016;57(4):648-59.

Masson M,Huberfeld G. What do antiepileptic drugs cure? Positive effects and side effects of antiepileptic drugs in psychiatry. Annales Medico-Psychologiques2016; 174 : 128–134. 

Masson M, Huberfeld G, Richa S, Henry C, Gaillard R. Caution and warning: About valproate and pregnancy.Encephale2016 ;42(5):391-394.

Depauw A, Dossi E, Kumar N, Fiorini-Debuisschert C, Huberfeld G, Ha-Thi MH, Rouach N, Leray I. A Highly Selective Potassium Sensor for the Detection of Potassium in Living Tissues. Chemistry2016 ;22(42):14902-14911.

Buchin A, Chizhov A, Huberfeld G, Miles R, Gutkin B. Reduced efficacy of the KCC2 cotransporter promotes epileptic oscillations in a subiculum network model. J Neurosci2016, 36(46):11619-11633.

Horodyckid C, Canney M, Vignot A, Boisgard R, Drier A, Huberfeld G, François C, Prigent A, Santin MD, Adam C, Willer JC, Lafon C, Chapelon JY, Carpentier A. Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model. J Neurosurg 2016; 10:1-11.

Zanello M, Pagès M, Roux A, Peeters S, Dezamis E, Puget S, Devaux B, Sainte-Rose C, Zerah M, Louvel G, Dumont SN, Meder JF, Grill J, Huberfeld G, Chrétien F, Parraga E, Sauvageon X, Varlet P, Pallud J. Epileptic seizures in anaplastic gangliogliomas. Br J Neurosurg 2017;31(2):227-233      

Jozwiak S, Becker A, Cepeda C, Engel J Jr, Gnatkovsky V, Huberfeld G, Kaya M, Kobow K, Simonato M, Loeb JA. WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients? Epilepsia. 2017; 58(6):951-961..

Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol2017;133(3):603-607.  

Huberfeld G, Trebuchon A, Capelle L, Badier JM, Chen S, Lefaucheur JP, Gavaret M. Preoperative and intraoperative neurophysiological investigations for surgical resections in functional areas. Neurochirurgie2017; 63(3):142-149.

Vecht C, Royer-Perron L, Houillier C, Huberfeld G. Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management. Curr Pharm Des 2017; 23(42):6464-6487. 

Dossi E, Blauwblomme T, Moulard, J, Chever O, Vassile F, Guinard E, Le Bert M, Couillin I, Pallud J, Capelle L, Huberfeld G, Rouach N, Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy. Sci Transl Med 2018; 10, eaar3796.

Shorvon SD, Bermejo PE, Gibbs AA, Huberfeld G, Kälviäinen R. Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection. Epilepsy Behav 2018; 82:91-103.

Buchin A, Kerr CC, Huberfeld G, Miles R, Gutkin B. Adaptation and Inhibition Control Pathological Synchronization in a Model of Focal Epileptic Seizure. eNeuro2018 5;5(5).

Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, Blonski M, Mandonnet E, Guillevin R, Guyotat J, Taillandier L, Capelle L, Duffau H, Pallud J. Extent of Resection and Residual Tumor Thresholds for Postoperative Total Seizure Freedom in Epileptic Adult Patients Harboring a Supratentorial Diffuse Low-Grade Glioma. Neurosurgery 2018 Nov 5.

Blauwblomme T, Dossi E, Pellegrino C, Goubert E, Gal B, Varlet P, Rouach N, Nabbout R, Huberfeld G. Gamma-aminobutyric acidergic transmission underlies interictal epileptogenicity in pediatric focal cortical dysplasia. Ann Neurol 2019;85(2):204-217.

Gataullina S, Bienvenu T, Nabbout R, Huberfeld G, Dulac O. Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy. Dev Med Child Neurol. 2019

Menendez de la Prida L and Huberfeld G. Inhibition and oscillations in the human brain tissue in vitro. Neurobiology of Disease 2019, 125: 198-210.

Book chapters

LeDuigou C, Huberfeld G, Miles R. (2009) Recurrent synaptic actions and the genesis of epileptiform activity. Encyclopedia of Basic Epilepsy Research. (Ph Schwartzkroin Editor) p836-41.

Miles R, Blaesse P, Huberfeld G, Wittner L & Kaila K. Jasper’s Basic Mechanisms of the Epilepsies (R Olsen Editor). Chloride homeostasis and GABA signaling in temporal lobe epilepsy. 2012.

Highlighted invited presentations.

9th European SEEG course.Mechanisms of epileptogenicity (and growth) in brain tumors (Venise, Italy, 2/2018). 

12thEuropean Congress on Epileptology. Mechanisms underlying seizure generation around human glioma. (Prague, Czech Republic, 09/2016).

IBRO. Common mechanisms of generation of epileptic discharges in diverse human epileptic tissues (Budapest, Hungry, 04/2016).

Epilepsy Research UK Workshop. Chloride regulation and GABAergic signaling in tumor associated epilepsy (St Anne’s College, Oxford, UK, 03/2016).

XIII Workshop on Neurobiology of Epilepsy (WONOEP). Interictal epileptic discharges and high frequency oscillations localize cortical infiltration by glioma cells (Heybeliada Island, Istanbul, Turkey; 09/2015). 

9th Joint Meeting of the German and Austrian Society for Epileptology and the Swiss League against Epilepsy. Cortical GABAergic excitation contributes to epileptic activities around human glioma (Dresden, Germany, 04/2015).

30thInternational Epilepsy Congress. A route to seizure in human tissue: when basal GABAergic excitation meets hyperexcitability (Montreal, Canada, 06/2013).

6th International Epilepsy Colloquium. Tumoral epileptogenicity: how does it happen? (Cleveland, USA, 05/2013).

66thAmerican Epilepsy Society Annual Meeting. Signature, cells and signaling basis of human epileptic tissues in vitro. Symposium Validation of epilepsy biomarkers in humans: goals, challenges, opportunities (San Diego, USA, 12/2012).

Gordon Research Conference: Mechanisms of Epilepsy & Neuronal Synchronization. Dynamic of the transition to seizures in human epileptic tissues (Waterville, Main, USA, 08/2012).

13thEuropean Congress of Epileptology. GABAergic excitatory mechanisms are involved in the genesis of epileptic activities in the cortex surrounding glioma in humans (London, UK, 09/2012).

Master Class « The five Ages of Epilepsy ». Neurophysiological markers of epileptogenicity (Salzbourg, Austria, 11/2011).

29thInternational Epilepsy Congress. A common GABAergic signaling defect in human epileptic lesions (Roma, Italy, 08/2011).

XI Workshop on the Neurobiology of Epilepsy (WONOEP). Common GABAergic signaling defects in human epileptic lesions (Roma, Italy, 08/2011).

First International Symposium on Brain-Tumor Related Epilepsy. Mechanisms of epileptic activity on peritumoral tissues (San Servolo, Venice, Italy, 07/2011).

Advanced International Course: From Basic Knowledge and Clinical Trials to Rational Prescribing in Epilepsy. Neurobiology of drug resistance in Epilepsy (San Servolo, Venice, Italy, 07/2011).

Hippocampus beneath the surface: A conference on hippocampus cells & networks, functions & abnormal activities. Transition to seizures in the epileptic postopertive subiculum in vitro (Presqu’île de Giens, France, 09/2010). 

Federation of European Neuroscience Societies (FENS). Cellular and network properties of the genesis of ictal discharges in human epileptic tissue (Amsterdam, Netherlands, 07/2010).

28thInternational Epilepsy Congress. Pyramidal cells & interneurons interactions in the initiation of ictal discharges in human epileptic tissue in vitro (Buapest, Hungary, 06/2009).

X Workshop on the Neurobiology of Epilepsy (WONOEP). Pharmacology of the dynamic to seizures in human epileptic tissue in vitro (Pecs, Hungary 06/2009).

61th American Epilepsy Society annual meeting – Investigators workshop. Transition to ictal events in human temporal lobe epilepsy in vitro:  population activities, GABAergic and glutamatergic signals (Philadelphia, USA, 11/2007).

36th Society for Neurosciences Annual Meeting. Interplay between GABAergic and glutamatergic signals in the genesis of ictal events in human temporal lobe epilepsy (San Diego, USA, 11/2007).

IX Workshop on the Neurobiology of Epilepsy (WONOEP). A double transmitter switch in the transition from interictal to ictal activity in human temporal lobe epilepsy in vitro (Langkawi, Malaysia, 07/2007).

7thEuropean Epilepsy Congress. Perturbed expression of the K-Cl cotransporter KCC2 and GABAergic signaling in human temporal lobe epilepsy (Helsinki, Finland, 07/2006).

26thInternational Epilepsy Congress – Basic Science Plateform session. Diuretics block human epileptiform activity in vitro (Paris, France 08/2005).